Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy

Next Previous
Trial Profile

Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms SUSTAIN; SUSTAIN JAPAN
  • Sponsors Novo Nordisk

Most Recent Events

  • 25 Sep 2020 Results (n=9680) of analysis from twelve clinical studies: SUSTAIN 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 and two Japanese SUSTAIN trials assessing risk predictors for Gastrointestinal adverse events with once weekly subcutaneous Semaglutide identifying high-risk patients presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
  • 01 Aug 2018 Results published in the Diabetes Therapy.
  • 15 Dec 2017 According to a Novo Nordisk media release, the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Ozempic (semaglutide) for the treatment of adults with type 2 diabetes mellitus.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top